How much is vrpx stock worth?
One share of VRPX stock can currently be purchased for approximately $2.81. How much money does Virpax Pharmaceuticals make? Virpax Pharmaceuticals has a market capitalization of $32.92 million.
What does vrpx stand for?
WEST CHESTER, PA / ACCESSWIRE / February 19, 2021 / Virpax Pharmaceuticals Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing pharmaceutical products for pain management, today announced the closing of its initial public offering of 1,800,000 shares of its common stock at a public offering price of $10.
Where can I buy virpax pharmaceuticals (vrpx)?
Shares of VRPX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Virpax Pharmaceuticals' stock price today?
Is virpax pharmaceuticals oversold on RSI 14?
Virpax Pharmaceuticals, Inc. is oversold on RSI14 (19). Some stocks may drop long and hard while being oversold on RSI before turning, which increases the general risk. Our recommended stop-loss: We hold an negative evaluation for this stock. No stop-loss is set. Is Virpax Pharmaceuticals, Inc. stock A Buy?
What is Virpax 2021?
What is Virpax Probudur?
Who is Virpax's financial advisor?
When is Virpax LD Micro Invitational 2021?
See more
About this website
Is VRPX a good stock to buy?
The Virpax Pharmaceuticals, Inc. stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. On corrections up, there will be some resistance from the lines at $1.58 and $1.57. A break-up above any of these levels will issue buy signals.
Is Virpax a buy?
Virpax Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Should I buy or sell Virpax Pharmaceuticals stock right now?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Virpax Pharmaceuticals in the last year. There are currently 2 buy ratings...
What is Virpax Pharmaceuticals' stock price forecast for 2022?
2 brokers have issued twelve-month price objectives for Virpax Pharmaceuticals' stock. Their forecasts range from $4.00 to $4.00. On average, they...
How has Virpax Pharmaceuticals' stock price performed in 2022?
Virpax Pharmaceuticals' stock was trading at $3.43 on January 1st, 2022. Since then, VRPX stock has decreased by 55.4% and is now trading at $1.53....
Are investors shorting Virpax Pharmaceuticals?
Virpax Pharmaceuticals saw a drop in short interest in May. As of May 31st, there was short interest totaling 87,600 shares, a drop of 35.0% from t...
When is Virpax Pharmaceuticals' next earnings date?
Virpax Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022. View our earnings forecast fo...
Who are Virpax Pharmaceuticals' key executives?
Virpax Pharmaceuticals' management team includes the following people: Mr. Anthony P. Mack M.B.A. , Chairman & CEO (Age 60, Pay $600k) ( LinkedI...
Who are some of Virpax Pharmaceuticals' key competitors?
Some companies that are related to Virpax Pharmaceuticals include IMV (IMV) , NightHawk Biosciences (NHWK) , Merrimack Pharmaceuticals (MACK) ,...
When did Virpax Pharmaceuticals IPO?
(VRPX) raised $15 million in an IPO on Wednesday, February 17th 2021. The company issued 1,400,000 shares at a price of $10.00-$12.00 per share. Th...
What is Virpax Pharmaceuticals' stock symbol?
Virpax Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRPX."
VRPX Stock Forecast, Price & News (Virpax Pharmaceuticals)
2.6 News and Social Media Coverage. News Sentiment Virpax Pharmaceuticals has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news).
VRPX Stock Price | Virpax Pharmaceuticals Inc. Stock Quote (U.S ...
VRPX | Complete Virpax Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
Virpax Pharmaceuticals, Inc. (VRPX) Stock Price, Quote & News | Stock ...
Analyst Forecast. According to 7 analysts, the average rating for VRPX stock is "Buy." The 12-month stock price forecast is 4.08, which is an increase of 150.31% from the latest price.
VRPX Virpax Pharmaceuticals Inc — Stock Price and Discussion | Stocktwits
Real-time trade and investing ideas on Virpax Pharmaceuticals Inc VRPX from the largest community of traders and investors.
Virpax Pharmaceuticals Inc (VRPX) Stock Price & News - Google
Get the latest Virpax Pharmaceuticals Inc (VRPX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.
VRPX | Virpax Pharmaceuticals Inc. Profile | MarketWatch
Virpax Pharmaceuticals Inc. company facts, information and financial ratios from MarketWatch.
What is Virpax 2021?
("Virpax" or the "Company") (NASDAQ: VRPX), today announced that the Investigational New Drug (IND) Application enabling studies for Envelta™ being performed under a Cooperative Research and Development Agreement (CRADA) enter ed into by Virpax and the National Center for Advancing Translational Sciences (NCATS) for chronic pain, will also be used as a source for INDs for two additional indications, for cancer pain and Post-Traumatic Stress
What is Virpax Probudur?
The rabbit limbs dosed with the liposomal prolonged bupivacaine release (Probudur), at ten times more than free bupivacaine, showed no nerve damage signs. Further, nerves injected with Probudur showed mild signs of inflammation and small residues of the hydrogel in granulomas, indicating a long residence time of the hydrogel at the injection site, but no histopathological signs of nerve damage. Price Action: VRPX shares are up 5.26% at $5.1 during the market trading session on the last check Monday. See more from BenzingaClick here for options trades from BenzingaJohnson & Johnson Becomes Third Company To Expand COVID-19 Vaccine Study To AdolescentsMolecular Templates Stock Falls After It Stops MT-3724 Development In Hematological Malignancies© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Who is Virpax's financial advisor?
Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), today announced that the Company has engaged Torreya Capital, LLC (Torreya) to serve as the exclusive financial advisor for the Company's partnering and licensing efforts in strategic global markets.
When is Virpax LD Micro Invitational 2021?
("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive, non-opioid pharmaceutical products for pain management, today announced that it will be presenting virtually at the upcoming LD Micro Invitational XI event on Wednesday, June 9, 2021 at 4:30 PM ET.
Virpax Pharmaceuticals Recaps Milestones and Highlights Product Portfolio
BERWYN, Pa.-- (BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX) achieved significant milestones relating to its pipeline of product candidates as of the e...
Virpax Pharmaceuticals Reports 2021 Third Quarter Results and Recent Developments
BERWYN, Pa.-- (BUSINESS WIRE)-- #earnings--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), today announced its financial results for the three and nine months ended September 30,...
Virpax to Present at the NobleCon Online Pain Management Investor Forum on Channelchek.com on October 7, 2021
BERWYN, Pa.-- (BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), a company specializing in developing product candidates for pain management, CNS disorder...
Best Penny Stocks To Buy Today? Retail Traders Are Watching These Now
Penny stocks bouncing back after the stock market sell-off The post Best Penny Stocks To Buy Today? Retail Traders Are Watching These Now appeared first on Penny Stocks to Buy, Picks, News and Informati...
Virpax to Develop Intranasal Cannabidiol Product for the Management of Epilepsy in Adults and Children
BERWYN, Pa.-- (BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), a company specializing in developing product candidates for pain management, CNS disorder...
Virpax Announces MMS019 Manufacturing and Supply Agreement
BERWYN, Pa.-- (BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing product candidates for pain management, CNS and anti...
Ideas
One more COVID idea, could just grab some commons and wait to see if there is any merit to their Antiviral nasal spray. In on some commons at $4.40, will wait a few weeks to see if this catches any strength
Profile
Virpax Pharmaceuticals, Inc. is a preclinical stage biopharmaceutical company, which engages in the development of branded, non-addictive pain management products. Its products include metered-dose spray, liposomal gel encapsulates, and intranasal spray. The company was founded by Anthony P. Mack and Jeffrey A.
What is Virpax 2021?
("Virpax" or the "Company") (NASDAQ: VRPX), today announced that the Investigational New Drug (IND) Application enabling studies for Envelta™ being performed under a Cooperative Research and Development Agreement (CRADA) enter ed into by Virpax and the National Center for Advancing Translational Sciences (NCATS) for chronic pain, will also be used as a source for INDs for two additional indications, for cancer pain and Post-Traumatic Stress
What is Virpax Probudur?
The rabbit limbs dosed with the liposomal prolonged bupivacaine release (Probudur), at ten times more than free bupivacaine, showed no nerve damage signs. Further, nerves injected with Probudur showed mild signs of inflammation and small residues of the hydrogel in granulomas, indicating a long residence time of the hydrogel at the injection site, but no histopathological signs of nerve damage. Price Action: VRPX shares are up 5.26% at $5.1 during the market trading session on the last check Monday. See more from BenzingaClick here for options trades from BenzingaJohnson & Johnson Becomes Third Company To Expand COVID-19 Vaccine Study To AdolescentsMolecular Templates Stock Falls After It Stops MT-3724 Development In Hematological Malignancies© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Who is Virpax's financial advisor?
Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), today announced that the Company has engaged Torreya Capital, LLC (Torreya) to serve as the exclusive financial advisor for the Company's partnering and licensing efforts in strategic global markets.
When is Virpax LD Micro Invitational 2021?
("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive, non-opioid pharmaceutical products for pain management, today announced that it will be presenting virtually at the upcoming LD Micro Invitational XI event on Wednesday, June 9, 2021 at 4:30 PM ET.
